Comirnaty® booster dose displays high efficacy in Phase III study
The vaccine showed a relative vaccine efficacy of 95.6 percent and is the first efficacy results from a COVID-19 vaccine booster trial.
List view / Grid view
The vaccine showed a relative vaccine efficacy of 95.6 percent and is the first efficacy results from a COVID-19 vaccine booster trial.
Scientists have developed a stabiliser-free, non-toxic poly(lactic-co-glycolic acid) (PLGA) nanoparticle formulation for use in drug and vaccine delivery.
A Swedish study found that heterologous Vaxzevria and mRNA prime-boost vaccination is effective against COVID-19.
Save up to 88% of deceleration time for your PBMC isolation due to optimized breaking ramps of Eppendorf Centrifuge 5910 Ri.
Join Mettler Toledo's Dr Hans-Joachim Muhr as he explains the key quality considerations for mRNA vaccines and why UV/Vis spectrophotometry should be applied in their QA/QC.
18 October 2021 | By 908Devices
In this on-demand webinar, 908 Devices present a microfluidic capillary zone electrophoresis-based separation coupled with HRAM mass-spectrometry for rapid characterisation of oligos in positive ionisation mode.
This webinar considers the problems bacterial and fungal spores present for contamination control and remediation and disinfection strategies.
Sanofi’s Fluzone® with Moderna’s COVID-19 mRNA investigational booster dose showed an immunogenicity response similar to individual doses.
Moderna will build an mRNA facility in Africa to manufacture 500 million doses of their COVID-19 vaccine and other products per year.
The World Health Organization (WHO) recommends GSK's RTS,S/AS01 (RTS,S) malaria vaccine for use in children in sub-Saharan Africa.
The pharma industry will need to outsource manufacturing for COVID-19 vaccine doses for booster doses and children, reports GlobalData.
The EMA concludes that booster doses of the COVID-19 vaccines Comirnaty and Spikevax can be given to people with severely weakened immune systems.
The EMA’s drug safety committee (PRAC) assessed risks of thrombocytopenia and venous thromboembolism with the Janssen COVID-19 Vaccine.
New study finds patients receiving chemotherapy have lower COVID-19 antibody levels post-vaccination than patients receiving targeted cancer therapy.
The investigational respiratory syncytial virus (RSV) vaccine candidate demonstrated 80 percent efficacy in adults aged 65 and older.